| scholarly article | Q13442814 |
| P50 | author | Jeffrey L. Saver | Q38328269 |
| Christopher J. Weir | Q44257156 | ||
| Keith Muir | Q73007450 | ||
| Sidney Starkman | Q110243430 | ||
| Chelsea S. Kidwell | Q110243582 | ||
| P2093 | author name string | Jeffry R Alger | |
| Deidre A De Silva | |||
| Kennedy R Lees | |||
| Stephen M Davis | |||
| Christopher Chen | |||
| MR IMAGES Investigators | |||
| P2860 | cites work | Classification and natural history of clinically identifiable subtypes of cerebral infarction | Q28244314 |
| Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. | Q30882783 | ||
| Proof-of-principle phase II MRI studies in stroke: sample size estimates from dichotomous and continuous data. | Q31056850 | ||
| Recommendations for standards regarding preclinical neuroprotective and restorative drug development | Q33785562 | ||
| Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview | Q34093891 | ||
| New imaging strategies for patient selection for thrombolytic and neuroprotective therapies | Q34365515 | ||
| Which MR-derived perfusion parameters are the best predictors of infarct growth in hyperacute stroke? Comparative study between relative and quantitative measurements. | Q34629122 | ||
| Magnesium in stroke treatment. | Q35032195 | ||
| Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study | Q36244107 | ||
| Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging | Q36714953 | ||
| The past and future of neuroprotection in cerebral ischaemic stroke | Q36961362 | ||
| Optimal definition for PWI/DWI mismatch in acute ischemic stroke patients | Q37701383 | ||
| Mg2+ administered up to twenty-four hours following reperfusion prevents ischemic damage of the Ca1 neurons in the rat hippocampus | Q41170947 | ||
| Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators | Q43678233 | ||
| Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. | Q44060062 | ||
| Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. | Q44534396 | ||
| Trends in acute ischemic stroke trials through the 20th century | Q46087072 | ||
| Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator | Q47405008 | ||
| The use of PWI and DWI measures in the design of "proof-of-concept" stroke trials | Q47737649 | ||
| Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke | Q48143612 | ||
| Magnesium for treatment of acute lacunar stroke syndromes: further analysis of the IMAGES trial. | Q48249416 | ||
| Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study | Q48387069 | ||
| Dose optimization of intravenous magnesium sulfate after acute stroke | Q48465392 | ||
| Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke | Q48491607 | ||
| Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats | Q48626944 | ||
| Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial | Q48913482 | ||
| Does the mismatch match the penumbra? Magnetic resonance imaging and positron emission tomography in early ischemic stroke | Q48954600 | ||
| Magnesium reduces N-methyl-D-aspartate (NMDA)-mediated brain injury in perinatal rats | Q49103959 | ||
| Intravenous administration of magnesium sulfate in acute stroke: a randomized double-blind study. | Q51360850 | ||
| Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. | Q51568433 | ||
| A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. | Q51601019 | ||
| Effect of Intravenous Thrombolysis on MRI Parameters and Functional Outcome in Acute Stroke <6 Hours | Q56971524 | ||
| Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial | Q57313084 | ||
| Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke | Q58619430 | ||
| The Desmoteplase in Acute Ischemic Stroke Trial (DIAS) | Q61649875 | ||
| Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset | Q83018902 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | magnesium | Q660 |
| P304 | page(s) | 1704-1709 | |
| P577 | publication date | 2009-03-19 | |
| P1433 | published in | Stroke Journal | Q7624282 |
| P1476 | title | Results of the MRI substudy of the intravenous magnesium efficacy in stroke trial | |
| P478 | volume | 40 |
| Q47979073 | Effect of magnesium treatment and glucose levels on delayed cerebral ischemia in patients with subarachnoid hemorrhage: a substudy of the Magnesium in Aneurysmal Subarachnoid Haemorrhage trial (MASH-II). |
| Q37639858 | The prognostic values of leukocyte Rho kinase activity in acute ischemic stroke |
| Q39427028 | The role of magnesium sulfate in the intensive care unit |
Search more.